Lipoprotein (a)

Alberico L. Catapano, Magdalena Daccord, Elaine Damato, Steve E. Humphries, R. Dermot G. Neely, Børge G. Nordestgaard, Michele Pistollato, Elisabeth Steinhagen-Thiessen. How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)? Atherosclerosis, 2022
Burgess, S., Ference, B et al (2018) Association of LPA variants with risk of coronary disease and the implications for Lipoprotein (a) lowering therapies: A mendelian randomization analysis. JAMA Cardiology. 3. 7. pp 619-672. Full review available
O'Donoghue, M. et al (2019) Lipoprotein (a), PCSK9 inhibition and Cardiovascular Risk: Insights from the FOURIER Trial. Circulation. Vol 139, No 12. pp1483-1492. Abstract available here
Pare, G et al (2019) Lipoprotein (a) Levels and the Risk of Myocardial Infarction among 7 Ethnic Groups. Circulation. Vol 138. No 12. pp1472-1482. Abstract available here
Thanassoulis, G. (2019) Editorial. Screening for High Lipoprotein (a). The Time is Now. Circulation. Vol 139. pp1493-1496. Full editorial available here